mTOR, translation initiation and cancer
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Control of mRNA translation plays a fundamental role in many aspects of cell metabolism. It constitutes a critical step in the control of gene expression, and consequently cell growth, proliferation and differentiation. Translation is regulated in response to nutrient availability, hormones, mitogenic and growth factor stimulation and is coupled with cell cycle progression and cell growth. Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and thus cap-dependent translation are emerging as promising therapeutic options for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a shift has been associated with proliferation in tumorigenesis, and has been linked to the translational control of RPs (Mamane et al., 2006; Ruggero and Sonenberg, 2005).”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Mamane et al., 2006
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 5×
“…factors and hormones) with aminoacid availability and intracellular energy status to control translation rates and additional metabolic processes (Hay and Sonenberg, 2004) (Figure 2). mTOR has received considerable attention, as rapamycin (Rapamune) is a specific inhibitor of mTOR activity (for…”
BackgroundInfluentialSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“An important downstream target of this signaling pathway is cap-dependent mRNA translation (Hay and Sonenberg, 2004; Hennessy et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the…”
BackgroundeIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationRegulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationHolz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239 · cited 1×
“…Heat and Acid-Stable protein regulated by Insulin) and 4E-BP2, were identified in a screen using radiolabelled recombinant eIF4E protein to probe a human placenta expression library (Pause et al., 1994) and by sequencing the complementary DNA (cDNA) clone for PHAS-I (Hu et al., 1994).”
BackgroundSelf-citationMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093 · cited 1×
“Enhancement of the eIF4E/4E-BP interaction, through the expression of a constitutively active 4E-BP mutant (all phosphorylation sites mutated to Ala), leads to a decrease in cell size and inhibition of cell cycle progression in a manner that mimics rapamycin treatment (Fingar et al., 2002, 2004).”
BackgroundKim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961 · cited 1×
“…et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the 4E-BPs (Gingras et al., 2001; Jacinto and Hall, 2003; Kim et al., 2003; Ruggero and Pandolfi, 2003; Kim and Sabatini, 2004).”
BackgroundMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956 · cited 1×
“…binding (Gingras et al., 1999b). eIF4G recruits the 40S small ribosomal subunit to the mRNA through the ribosomeassociated eIF3. eIF4E eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cul- tured rodent cells (Lazaris-Karatzas et al., 1990).”
BackgroundSelf-citationSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951 · cited 1×
“Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004).”
Background
Cited by
Items 301–400 of 618
The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model
y Cajal, S. R. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1118 · Cited by 38
Felczykowska, A., Pawlik, A., Mazur‐Marzec, H., Toruńska-Sitarz, A., Narajczyk, M., Richert, M., Węgrzyn, G., & Herman-Antosiewicz, A. (2015) · Toxicon · doi:10.1016/j.toxicon.2015.09.030 · Cited by 35
Lussier, C. R., Brial, F., Roy, S. A. B., Langlois, M., Verdu, E. F., Rivard, N., Perreault, N., & Boudreau, F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012378 · Cited by 35
“It has been well described that Pten, through inactivation of Akt, can negatively control translation mechanisms through its regulation of mTOR/ S6K signalling, thus influencing cell growth and protein synthesis [22].”
BackgroundActivation of p53 stimulates proteasome‐dependent truncation of eIF4E‐binding protein 1 (4E‐BP1)
Constantinou, C., Elia, A., & Clemens, M. J. (2008) · Biology of the Cell · doi:10.1042/bc20070121 · Cited by 33
“On the other hand, growth-inhibitory conditions and a variety of physiological stresses that cause down-regulation of protein synthesis bring about dephosphorylation of 4E-BP1 (Mamane et al., 2006).”
BackgroundInfluentialThomé, C. H., dos Santos, G. A., Ferreira, G. A., Scheucher, P. S., Izumi, C., Leopoldino, A. M., Simão, A. M., Ciancaglini, P., de Oliveira, K. T., Chin, A. P., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.019661 · Cited by 33
“Indeed, phosphorylation of 4EBP-1 and ribosomal S6 kinase (RS6K) and up-regulation of cap-dependent translation in the ribosome is downstream of PI3K/AKT/mTOR (51, 67, 68).”
BackgroundTranslational up‐regulation of Aurora‐A in EGFR‐overexpressed cancer
Lai, C.-H., Tseng, J. T.-C., Lee, Y., Chen, Y., Lee, J.-C., Lin, B., Huang, T., Liu, Y., Leu, T., Liu, Y., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00919.x · Cited by 38
“It organizes a critical step for the control of gene expression, and hence cell growth, proliferation and differentiation [10].”
BackgroundPoillet-Perez, L., Jacquet, M., Hervouet, É., Gauthier, T., Fraîchard, A., Borg, C., Pallandre, J., Gonzalez, B. J., Ramdani, Y., Boyer‐Guittaut, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19639 · Cited by 34
“GABARAPL1 and GABARAPL1 G116A could present a tumor suppressor role through the inhibition of MTOR which has been previously shown to be involved in cell proliferation and tumor progression [69-71].”
BackgroundEl-Hanboshy, S. M., Helmy, M. W., & Abd-Alhaseeb, M. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06715-0 · Cited by 32
“Consequently, translation of various essential proliferative and angiogenic factors, like cyclinD1, c-myc, VEGF and HIF1α, is regulated by both of those proteins [33, 34].”
BackgroundGlutamine deficiency in solid tumor cells confers resistance to ribosomal RNA synthesis inhibitors
Pan, M., Zorbas, C., Sugaya, M., Ishiguro, K., Kato, M., Nishida, M., Zhang, H., Candeias, M. M., Okamoto, A., Ishikawa, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31418-w · Cited by 33
Kang, B., Hao, C., Wang, H., Zhang, J., Xing, R., Shao, J., Li, W., Xu, N., Lu, Y., & Liu, S. (2008) · Journal of Proteome Research · doi:10.1021/pr800238p · Cited by 32
Everolimus – a new approach in the treatment of renal cell carcinoma
Eisen, T. G. (2010) · Cancer Management and Research · doi:10.2147/cmar.s6047 · Cited by 41
“The mTOR kinase also controls angiogenic pathways via hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and via endothelial and smooth muscle cell proliferation which have been implicated in the etiology of clear cell renal cell carcinoma.(14,15) Rapalogs have long been known to inhibit t…”
Kikani, C. K., Antonysamy, S., Bonanno, J. B., Romero, R., Zhang, F. F., Russell, M., Gheyi, T., Iizuka, M., Emtage, J. S., Sauder, J. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157594 · Cited by 41
Multi-omic molecular profiling of lung cancer in COPD
Sandri, B. J., Kaplan, A. N., Hodgson, S. W., Peterson, M., Avdulov, S. V., Higgins, L., Markowski, T. W., Yang, P., LIMPER, A. H., Griffin, T. J., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02665-2017 · Cited by 37
Inflammatory Conditions Induce IRES-Dependent Translation of cyp24a1
Rübsamen, D., Kunze, M. M., Buderus, V., Brauß, T. F., Bajer, M. M., Brüne, B., & Schmid, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085314 · Cited by 32
“In addition, mTOR inhibits the 4E-binding protein (4E-BP), which upon mTOR-dependent hyperphosphorylation releases the cap-binding protein eIF4E, thus allowing for initiation of capdependent translation [4,5].”
BackgroundThe promise of mTOR inhibitors in the treatment of colorectal cancer
Kim, D.-D., & Eng, C. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.721353 · Cited by 33
“Thus, mTOR plays a key role in cellular growth and homeostasis, and its regulation is frequently altered in tumors [20,21].”
BackgroundArctigenin alleviates ER stress via activating AMPK
Gu, Y. J., Sun, X., Ye, J., He, L., Yan, S., Zhang, H., Hu, L., Yuan, J., & Yu, Q. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.60 · Cited by 32
“The most characterized downstream effectors of mTOR are p70S6K and the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), through which mTOR stimulates the initiation step of translation [24] .”
BackgroundMark, M. T., Klingbiel, D., Mey, U., Winterhalder, R., Rothermundt, C. A., Gillessen, S., von Moos, R., Pollak, M., Manetsch, G., Strebel, R. T., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.12.009 · Cited by 33
Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence
Chao, S. K., Horwitz, S. B., & McDaid, H. M. (2011) · Oncotarget · doi:10.18632/oncotarget.221 · Cited by 33
“4E-BP1 undergoes hierarchical phosphorylation by mTORC1 leading to its activation, reviewed in [47].”
BackgroundAbrogating GPT2 in triple‐negative breast cancer inhibits tumor growth and promotes autophagy
Mitra, D., Vega-Rubín-de-Celis, S., Royla, N., Bernhardt, S., Wilhelm, H., Tarade, N., Poschet, G., Buettner, M., Binenbaum, I., Borgoni, S., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33456 · Cited by 33
“Consistent with this, we found that KO of GPT2 results in decreased mTORC1 activity as seen by the reduced phosphorylation levels of downstream effectors of the pathway, p70s6k and 4EBP1.(44,45) Our in vitro findings were substantiated upon in vivo testing, as growth of xenograft tumors was massively impeded in the ab…”
ResultIncreased Susceptibility of Breast Cancer Cells to Stress Mediated Inhibition of Protein Synthesis
Pervin, S., Tran, A., Zekavati, S., Fukuto, J. M., Singh, R., & Chaudhuri, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0074 · Cited by 33
The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues
Añazco-Guenkova, A. M., Miguel‐López, B., Monteagudo-García, Ó., García-Vílchez, R., & Blanco, S. (2024) · NAR Cancer · doi:10.1093/narcan/zcae012 · Cited by 31
“Many mTOR inhibitors have been developed, but only a few of them have been approved to treat human cancer; the majority of mTOR inhibitors are currently undergoing evaluation in clinical trials ( 7 ).”
BackgroundPark, Y. Y., Ahn, J.-H., Cho, M.-G., & Lee, J. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0069-2 · Cited by 32
Tabibzadeh, A., Tameshkel, F. S., Moradi, Y., Soltani, S., Moradi‐Lakeh, M., Ashrafi, G. H., Motamed, N., Zamani, F., Motevalian, S. A., Panahi, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73770-1 · Cited by 30
Pande, M., Bondy, M. L., Do, K.-A., Şahin, A. A., Ying, B., Mills, G. B., Thompson, P. A., & Brewster, A. M. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3081-9 · Cited by 38
“Although the modifying effect of obesity on prognostic breast tumor characteristics has been studied extensively [3, 4], there are limitations in our understanding of the contribution of genes involved in obesity-related signaling pathways to breast cancer outcomes.”
BackgroundZeng, G., Cui, X., Liu, Z., Zhao, H., Zheng, X., Zhang, B., & Xia, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813236 · Cited by 32
“[21] reported that PLCγ was required for Akt activation (Ser473) that is responsible for the triggering of MTORC1/S6 pathway [22].”
BackgroundStress-resistant Translation of Cathepsin L mRNA in Breast Cancer Progression
Tholen, M., Wolanski, J., Stolze, B., Chiabudini, M., Gajda, M. R., Bronsert, P., Stickeler, E., Rospert, S., & Reinheckel, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624353 · Cited by 29
“Chemical inhibition of mTORC1 is a more defined way to suppress translation (19) and might give us further insight into stress-resistant translation of CTSL.”
BackgroundHypoxia‐induced regulation of mTOR signaling by miR‐7 targeting REDD1
Seong, M., Lee, J., & Kang, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27740 · Cited by 29
“Exposure to hypoxia significantly inhibited the phosphorylation of S6K1 (Thr389) in HeLa cells (Figure 1A), consistent with the well‐known role of hypoxia to inhibit mTOR signaling.(18) Moreover, as an upstream regulator in hypoxia‐induced mTOR signaling, quantitative reverse transcriptase‐PCR (qRT‐PCR) and immunoblot…”
BackgroundThe steady-state expression of connexin43 is maintained by the PI3K/Akt in osteoblasts
Bhattacharjee, R., Kaneda, M., Nakahama, K., & Morita, I. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.044 · Cited by 31
Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells
Mogi, M., & Kondo, A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.084 · Cited by 29
Pentamidine reduces expression of hypoxia-inducible factor-1α in DU145 and MDA-MB-231 cancer cells
Jung, H.-J., Suh, S., Suh, M., Baek, W., & Park, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.008 · Cited by 31
Lineham, E., Spencer, J., & Morley, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0062 · Cited by 32
Lu, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.970654 · Cited by 33
“Inactivation of 4EBP, an inhibitor of eIF4E, by mTORC1-mediated phosphorylation is also a common event in cancer (Mamane et al., 2006).”
BackgroundGalán, A., Dergham, P., Escoll, P., de-la-Hera, A., D’Onofrio, P. M., Magharious, M. M., Koeberle, P. D., Frade, J. M., & Saragovi, H. U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101349 · Cited by 30
“pAkt is also a surrogate marker of mTORC1 activity [16], and regulates cell growth and survival [17].”
BackgroundLi, J., Liu, J., Song, J., Wang, X., Weiss, H. L., Townsend, C. M., Gao, T., & Evers, B. M. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00067.2011 · Cited by 31
“Ribosomal p70S6 kinase (p70S6K) and eukaryotic translation initiation factor-4E (eIF4E) binding protein 1 (4E-BP1) are two of the best characterized downstream effectors in the regulation of mRNA translation (47).”
BackgroundMatsumoto, A., Ichikawa, T., Nakao, K., Miyaaki, H., Hirano, K., Fujimito, M., Akiyama, M., Miuma, S., Ozawa, E., Shibata, H., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0075-1 · Cited by 30
“Although mTOR is the mRNA translational regulator through phosphorylation of a downstream target such as 4E-BP and S6K [24], we think that the IFN-induced mTOR activity influences the phosphorylation of STAT-1 in our study (Fig.”
BackgroundLi, L., Liu, D., Qiu, Z.-X., Zhao, S., Zhang, L., & Li, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116771 · Cited by 27
“Then phosphorylated mTOR (p-mTOR) will activate P70S6K and inhibit 4EBP1, regulating ribosome biogenesis and protein synthesis[10].”
BackgroundPatrick, R. M., Lee, J. C. H., Teetsel, J. R. J., Yang, S.-H., Choy, G. S., & Browning, K. S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003945 · Cited by 29
“Activation of mTOR leads to phosphorylation of 4E-BPs, reducing their affinity for eIF4E and making the protein available for binding by eIF4G, increasing levels of translation initiation (7).”
BackgroundFunctional interactions between mRNA turnover and surveillance and the ubiquitin proteasome system
Brooks, S. A. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.11 · Cited by 31
Park, I. H., Kong, S., Kwon, Y., Kim, M. K., Sim, S. H., Joo, J., & Lee, K. S. (2018) · Journal of Cancer · doi:10.7150/jca.24035 · Cited by 29
“Dysregulation of the PI3K pathway by PIK3CA mutations has been found frequently in ER-positive breast cancer [6, 7].”
BackgroundTargeting autophagy in gastrointestinal malignancy by using nanomaterials as drug delivery systems
Raju, G. S. R., Pavitra, E., Merchant, N., Lee, H., Prasad, G. L. V., Nagaraju, G. P., Huh, Y. S., & Han, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.044 · Cited by 28
Characterization of Sin1 Isoforms Reveals an mTOR-Dependent and Independent Function of Sin1γ
Yuan, Y., Pan, B., Sun, H., Chen, G., Su, B., & Huang, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135017 · Cited by 27
“hydrophobic motif (HM) site phosphorylation [5], [6].”
Stuart, H., Jia, Z., Messenberg, A., Joshi, B., Underhill, T. M., Moukhles, H., & Nabi, I. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804014200 · Cited by 30
Liu, X., Mangla, R., Tian, W., Qiu, X., Li, D., Walter, K. A., EKHOLM, S. E., & Johnson, M. D. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2602-x · Cited by 26
Good, A. L., & Stoffers, D. A. (2020) · Diabetes · doi:10.2337/dbi18-0068 · Cited by 28
“For example, mTOR signaling increases protein synthesis in part via inactivation of the inhibitory factor 4E-BP1 to promote cellular growth and proliferation (48).”
BackgroundS6K1 phosphorylates Cdk1 and MSH6 to regulate DNA repair
Amar-Schwartz, A., Ben-Hur, V., Jbara, A., Cohen, Y., Barnabas, G. D., Arbib, E., Siegfried, Z., Mashahreh, B., Hassouna, F., Shilo, A., et al. (2022) · eLife · doi:10.7554/elife.79128 · Cited by 26
Biological functions and research progress of eIF4E
Chen, X., An, Y., Tan, M., Xie, D., Liu, L., & Xu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1076855 · Cited by 30
“Growth factors, mitogens, and hormones can activate the PI3K-AKT-mTOR signaling pathway (93).”
BackgroundSuer, S., Ampasala, D. R., Walsh, M. F., & Basson, M. D. (2009) · Cell and Tissue Research · doi:10.1007/s00441-009-0776-z · Cited by 26
“which in turn is crucial for cell growth, survival, and homeostasis (Mamane et al. 2006), we have sought to determine whether ERK and mTOR are involved in the TGFβ regulation of FAK expression in cultured rat IEC-6 intestinal epithelial cells.”
InfluentialRasool, R. U., Rah, B., Amin, H., Nayak, D., Chakraborty, S., Rawoof, A., Mintoo, M. J., Yousuf, K., Mukherjee, D., Kumar, L. D., et al. (2016) · Scientific Reports · doi:10.1038/srep18800 · Cited by 26
Li, S., Wang, Z., Huang, J. V., Cheng, S., Du, H., Che, G., & Peng, Y. (2016) · BMC Cancer · doi:10.1186/s12885-016-2940-7 · Cited by 26
“It is commonly recognized that mTOR encompasses two distant functional protein complexes in the organism, mTORC1 and mTORC2 [14].”
Hou, J.-N., Chen, T.-H., Chiang, Y., Peng, J., Yang, T.-H., Cheng, C.-C., Sofiyatun, E., Chiu, C., Chiang-Ni, C., & Chen, W. (2017) · Viruses · doi:10.3390/v9090262 · Cited by 27
“Since regula ion of cap-dependent translation has been r lated o TOR signaling [24], to access the activation of the TOR signaling pathway, its downstream target gene eIF4E-BP was detected due to the absence of an appropriate antibody for recognizing TOR activation in mosquito cells.”
BackgroundInfluentialXu, Q., Liu, X., Zhu, S., Hu, X., Niu, H., Zhang, X., Zhu, D., Nesa, E. U., Tian, K., & Yuan, H. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13475 · Cited by 28
“Phospho-4EBP1 (c-band, inactivation of 4EBP1 by mTORC1mediated phosphorylation) that enhances translation initiation complex formation and cap-dependent translation [21] was more evident after treatment (Fig.”
Bouvardin is a Radiation Modulator with a Novel Mechanism of Action
Stickel, S., Gomes, N. P., Frederick, B. A., Raben, D., & Su, T. T. (2015) · Radiation Research · doi:10.1667/rr14068.1 · Cited by 26
A collection of caged compounds for probing roles of local translation in neurobiology
Sadovski, O., Jaikaran, A. S. I., Samanta, S., Fabian, M. R., Dowling, R. J. O., Sonenberg, N., & Woolley, G. A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.04.005 · Cited by 30
Self-citationWu, Z., Tian, M., Heng, J., Chen, J., Chen, F., Guan, W., & Zhang, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00530 · Cited by 26
Inhibitory Effects of Butein on Cancer Metastasis and Bioenergetic Modulation
Liu, S., Chen, C., Chung, C., Wang, P., Wu, N., Cheng, J., Lai, Y., Sun, H., Peng, C.-Y., Tang, C., et al. (2014) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf502370c · Cited by 25
Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells
Wu, W. K. K., Volta, V., Cho, C. H., Wu, Y. C., Li, H. T., Yu, L., Li, Z. J., & Sung, J. J. �. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.080 · Cited by 25
NRSF/REST regulates the mTOR signaling pathway in oral cancer cells
Cho, E., Moon, S., Park, B. R., Kim, D. K., LEE, B.-K., & Kim, C. S. (2014) · Oncology Reports · doi:10.3892/or.2014.3675 · Cited by 28
“eIF4G is one of the fundamental downstream targets of the mTOR signaling pathway (26).”
BackgroundVender, J. R., Sukumari‐Ramesh, S., Singh, N., & Dhandapani, K. M. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.77029 · Cited by 25
“Mammalian target of rapamycin (mTOR), a serine/ threonine kinase involved in diverse cellular processes, including protein translation, mRNA turnover, and protein stability, mediates, at least in part, some of the biological actions of Akt.[2,3,11] Based on our recent demonstration that basal Akt activation increased…”
BackgroundInfluentialArf6 promotes cell proliferation via the PLD‐mTORC1 and p38MAPK pathways
Knizhnik, A. V., Kovaleva, O. V., Komelkov, A. V., Trukhanova, L. S., Александровна, Р. В., Zborovskaya, I. B., & Tchevkina, E. M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23362 · Cited by 28
“see [Averous and Proud, 2006; Mamane et al., 2006]).”
BackgroundSteroid and Oxygen Effects on eIF4F Complex, mTOR, and ENaC Translation in Fetal Lung Epithelia
Otulakowski, G., Duan, W., Gandhi, S. G., & O'Brodovich, H. M. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0055oc · Cited by 31
“As with 4E-BP, phosphorylation of S6K also enhances formation of the translation initiation complex and cap-dependent translation (39).”
Kim, J., Kim, K., Song, I. S., Cheon, K. S., Kim, O., Lee, S. C., Lee, S. K., & Kim, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13808 · Cited by 24
“Second, everolimus inhibits expression of anti-apoptotic proteins by activating the c-Jun N-terminal kinase (JNK) pathway [31, 32].”
BackgroundRetractedGuégan, J., Ezan, F., Gailhouste, L., Langouët, S., & Baffet, G. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24521 · Cited by 26
“…control of the cell cycle by the ERK pathway has been postulated to represent an important tumorigenesis barrier whose physiological importance has been demonstrated in vivo by the observation of cellular senescence in pre-malignant lesions (Collado et al., 2005; Michaloglou et al., 2005).”
BackgroundExpression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors
Alì, G., Boldrini, L., Capodanno, A., Pelliccioni, S., Servadio, A., Crisman, G., Picchi, A., Davini, F., Mussi, A., & Fontanini, G. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.291 · Cited by 24
mTOR Regulation of Metabolism in Hematologic Malignancies
Mirabilii, S., Ricciardi, M. R., & Tafuri, A. (2020) · Cells · doi:10.3390/cells9020404 · Cited by 26
Emerging treatment combinations: Integrating therapy into clinical practice
Wong, S. T.-L. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090439 · Cited by 24
Bitterman, P. B., & Polunovsky, V. A. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19610 · Cited by 27
“Microarray analysis of polyribosome-bound mRNA populations show that the principal target of activated eIF4F is a subset of transcripts that impact cell proliferation and survival.(5,10,34,116) The molecular mechanism by which upregulation of eIF4E alters translation of only a select subset of mRNA remains an area of…”
BackgroundNiacin protects against UVB radiation-induced apoptosis in cultured human skin keratinocytes
Lin, F., Xu, W., Guan, C., Zhou, M., Hong, W., Fu, L., Liu, D., & Xu, A. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.886 · Cited by 23
“S6K1 is another mTOR target that plays a role in the apoptosis resistance of cancer cells (48-50).”
Messina, V., Sauro, A. D., Pedrotti, S., Adesso, L., Latina, A., Geremia, R., Rossi, P., & Sette, C. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.110.085050 · Cited by 23
“The higher translational activity of spermatocytes is also supported by phosphorylation of rpS6, a well-known marker of active translation [23, 24].”
BackgroundInfluentialTuberous sclerosis—A model for tumour growth
Dodd, K. M., & Dunlop, E. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.025 · Cited by 24
Antineoplastic effects of mammalian target of rapamycine inhibitors
Salvadori, M. (2012) · World Journal of Transplantation · doi:10.5500/wjt.v2.i5.74 · Cited by 23
Peppenelli, M. A., Miller, M. J., Altman, A. M., Cojohari, O., & Chan, G. C. T. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.07.015 · Cited by 24
Wang, C., Maass, T., Krupp, M., Thieringer, F. R., Strand, S., Wörns, M., Barreiros, A. P., Galle, P. R., & Teufel, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.024 · Cited by 24
Chang, L.-S., Oblinger, J. L., Burns, S. S., Huang, J., Anderson, L. W., Hollingshead, M. G., Shen, R., Pan, L., Agarwal, G., Ren, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0809 · Cited by 22
“ThemTOR kinase phosphorylates and inactivates the eIF4E-binding protein translational repressors (18).”
BackgroundPhase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
Amato, R. J., Flaherty, A. L., & Stepankiw, M. (2011) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2011.11.002 · Cited by 22
Breast Carcinoma Cells in Primary Tumors and Effusions Have Different Gene Array Profiles
Konstantinovsky, S., Smith, Y., Zilber, S., Stavnes, H. T., Becker, A.-M., Nesland, J. M., Reich, R., & Davidson, B. (2009) · Journal of Oncology · doi:10.1155/2010/969084 · Cited by 22
“The relative phosphorylation extent of the mTORC1 substrate p70S6K [28, 29] was measured in order to analyze the effect of TSC1 downregulation on the mTORC1 activity.”
BackgroundChakravarthy, R., Clemens, M. J., Pirianov, G., Perdios, N., Mudan, S., Cartwright, J. E., & Elia, A. (2013) · Biology of the Cell · doi:10.1111/boc.201300021 · Cited by 22
“One important aspect of the cellular response to TRAIL is the control of protein synthesis (Jeffrey et al., 2002; Jeffrey et al., 2006), a complex process often dysregulated in tumour cells (Mamane et al., 2006; Robert and Pelletier, 2009).”
BackgroundPrognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer
Lu, Y., Deng, A., Li, L.-H., Liu, G., & Wu, G. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.36927 · Cited by 21
“Activated Akt phosphorylates PRAS40 on threonine 246, which in turn permits mTOR phosphorylation and activation [10, 11].”
BackgroundKuo, S., Hsu, C., Chen, L., Lu, Y., Lin, C.-H., Yeh, P.-Y., Jeng, H., Gao, M., Yeh, K., & Cheng, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.003 · Cited by 22
Duan, L., Ying, G., Danzer, B., Perez, R. E., Shariat‐Madar, Z., Levenson, V., & Maki, C. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.550038 · Cited by 25
“Depletion or Inhibition of PRCP and PREP Blocks Rapamycininduced Feedback Increase of IRS-1 and Activation of PI3K/AKT, and Enhances Rapamycin-induced Cytotoxicity—IRS-1-PI3KAKT signaling activates mTOR, which then phosphorylates and activates the ribosomal protein S6 kinase (S6K1) to promote protein translation and g…”
BackgroundNext generation of mammalian target of rapamycin inhibitors for the treatment of cancer
Nelson, V. M., Altman, J. K., & Platanias, L. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.787066 · Cited by 21
“The mammalian target of rapamycin (mTOR) complexes are effectors of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) network that regulates critical and essential cellular functions, including mRNA translation and protein synthesis [1-6].”
BackgroundMartín-Liberal, J., Gil-Martín, M., Sáinz‐Jaspeado, M., Gonzalo, N., Rigo, R., Colom, H., Muñoz, C., Tirado, Ò. M., & del Muro, X. G. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.370 · Cited by 20
“These proteins are involved in the biosynthesis of ribosomes and translation of mRNA necessary for normal cell-cycle regulation (Mamane et al, 2006).”
BackgroundInvolvement of 4E-BP1 in the Protection Induced by HDLs on Pancreatic β-Cells
Pétremand, J., Bulat, N., Butty, A.-C., Poussin, C., Rütti, S., Au, K. G., Ghosh, S., Mooser, V., Thorens, B., Yang, J.-Y., et al. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0448 · Cited by 24
mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice
Barthélémy, P., Hoch, B., Chevreau, C., Joly, F., Laguerre, B., Lokiec, F. M., & Duclos, B. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.02.006 · Cited by 21
“[7] Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N.”
BackgroundAnalysis of complex protein kinase B signalling pathways in human prostate cancer samples
Jendrossek, V., Henkel, M., Hennenlotter, J., Vogel, U. H., Ganswindt, U., Müller, I., Handrick, R., Anastasiadis, A. G., Kuczyk, M., Stenzl, A., et al. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07703.x · Cited by 21
Modelling and analysis of an ensemble of eukaryotic translation initiation models
Nayak, S., Siddiqui, J. K., & Varner, J. D. (2011) · IET Systems Biology · doi:10.1049/iet-syb.2009.0065 · Cited by 26
Amino acids metabolism: a potential target for cancer treatment
Ren, S., Zhou, X., Wang, Z., & Yuan, K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02523-3 · Cited by 22
“AMPK and mTORC1 monitor cellular energy and amino acid pools, and mTORC1 negatively regulates autophagy [58].”
MicroRNAs as the fine-tuners of Src oncogenic signalling
Oneyama, C., & Okada, M. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv036 · Cited by 20
“mTORC1 controls cell growth by regulating mRNA translation via phosphorylation of downstream substrates, ribosomal S6 kinase, and 4E binding protein 1 (30).”
BackgroundLee, M. Y., Jo, S. D., Lee, J., & Han, H. J. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21959 · Cited by 20
“Both these proteins are critical for translation of specific mRNAs involved in cell cycle progression, including cyclin D1 [Mamane et al., 2006].”
BackgroundNoncanonical translation via deadenylated 3′ UTRs maintains primordial germ cells
Jin, Y. N., Schlueter, P. J., Jurisch‐Yaksi, N., Lam, P., Jin, S., Hwang, W. Y., Yeh, J.-R. J., Yoshigi, M., Ong, S., Schenone, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0098-0 · Cited by 18
Tan, H., Gong, Y., Liu, Y., Long, J., Luo, Q., Faleti, O. D., & Lyu, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114916 · Cited by 20
“The application of rapamycin modifies the transcript levels of the immediate early proteins Z and R [175].”
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome
Jönsson, J.-M., Bartuma, K., Valentin, M. D., Harbst, K., Ketabi, Z., Malander, S., Jönsson, M., Carneiro, A., Måsbäck, A., Jönsson, G. B., et al. (2014) · Familial Cancer · doi:10.1007/s10689-014-9728-1 · Cited by 18
“cisplatin in sporadic ovarian cancer [23, 36, 37].”
Oulhen, N., Mulner‐Lorillon, O., & Cormier, P. (2009) · Molecular Reproduction and Development · doi:10.1002/mrd.21110 · Cited by 18
“The interaction between eIF4E1 and 4EBP1 is regulated by the phosphorylation status of 4E-BP1 through the PI3K/Akt/mTOR signaling pathway (review in Mamane et al., 2006).”
Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Kuo, W., Liu, J., Mauceri, H. J., Vokes, E. E., Weichselbaum, R. W., Rosner, M. R., & Cohen, E. E. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0352 · Cited by 19
Anti-tumour effect of metformin in canine mammary gland tumour cells
Saeki, K., Watanabe, M., Tsuboi, M., Sugano, S., Yoshitake, R., Tanaka, Y., Ong, S. M., Saito, T., Matsumoto, K., Fujita, N., et al. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.026 · Cited by 20
Temsirolimus for the treatment of mantle cell lymphoma
Heß, G. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.57 · Cited by 18
Nader, M., Chahine, N. R., Salem, C., & Chahine, R. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0510-8 · Cited by 17
Dai, M., Miao, Z., Ren, X., Tong, L., Yang, N., Li, T., Lin, L., Shen, Y., & Ding, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00822.x · Cited by 16
Maj‐Hes, A., Médioni, J., Scotté, F., Schmidinger, M., Kramer, G., Combe, P., Gornadha, Y., Elaidi, R., & Oudard, S. M. (2013) · Oncology · doi:10.1159/000350005 · Cited by 16
Chang, L., Tian, X., Lu, Y., Jia, M., Wu, P., & Huang, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099254 · Cited by 16
“The mammalian target of rapamycin (mTOR) signaling pathway determines the core route from PI3K to AKT and which diverges at mTOR [21], where it activates either ribosomal S6 kinase 1(S6K1)or the eukaryotic translation initiation factor 4E(eIF4E) [22].”
BackgroundRetractedNakamura, M., Miki, Y., Akahira, J., Morimoto, R., Satoh, F., Ishidoya, S., Arai, Y., Suzuki, T., Hayashi, Y., & Sasano, H. (2009) · Endocrine Pathology · doi:10.1007/s12022-009-9058-2 · Cited by 18
“In addition, 4E binding protein (4EBP) is the other direct target of mTOR [20].”
Background
Metadata
- Authors
- Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N.
- Affiliations
- McGill University (CA)
- Corresponding author
- Sonenberg, N
- ORCID
- Sonenberg, N
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6416-6422
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2165848665
- Cited by
- 607
- References
- 79
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 28 · 2022: 14 · 2021: 7 · 2020: 23 · 2019: 16 · 2018: 32 · 2017: 26 · 2016: 28 · 2015: 41 · 2014: 41 · 2013: 40 · 2012: 41
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTOR, mRNA translation, translation initiation, PI3K/AKT/mTOR pathway, 4E-BP, S6K, cap-dependent translation, cancer therapy, nutrient signaling, cell growth
- MeSH terms
- Animals, Gene Expression Regulation, Humans, Mammals, Models, Genetic, Neoplasms, Peptide Chain Initiation, Translational, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.